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The Psychiatric GWAS Consortium was founded with the aim of conducting statistically rigorous and
comprehensive GWAS meta-analyses for five major psychiatric disorders: ADHD, autism, bipolar disorder,
major depressive disorder, and schizophrenia. In the era of GWAS and high-throughput genomics, a major
trend has been the emergence of collaborative, consortia approaches. Taking advantage of the scale that
collaborative consortia approaches can bring to a problem, the PGC has been a major driver in psychiatric
genetics and provides a model for how similar approaches may be applied to other disease communities.Introduction
Genome-wideassociationstudies (GWAS)
have yielded an extraordinary and unprec-
edented troveof newknowledge about the
genetic causes of human disease. Since
2005, well over 600 human GWAS have
been published, yielding genetic associa-
tions meeting stringent statistical signifi-
cance (Pe’er et al., 2008) relevant to the
etiology of 92 diseases and 117other traits
(Hindorff et al., 2009).Manyof theseGWAS
findings have been surprising and have
engendered new ideas about disease
etiology. Because exposure to genetic
variation begins at the earliest stage of
development, we can generally be confi-
dent that genetic risk factors are at the
beginning of the causal chain that leads
to disease perhaps decades later. Thus,
each association is a starting point, a
hard clue about disease etiology. As an
example from outside of neuroscience, in
Crohn’s disease, GWAS implicated genes
involved in macroautophagy which has
provided important insights intopathogen-
esis (Klionsky, 2009). The notably strong
association of complement factor H (CFH)
with age-related macular degeneration
has engendered renewed interest in the
role ofCFH in initiating thediseaseprocess
rather than as epiphenomenon associated
with thedisease. In schizophrenia,multiple
independent studies have implicated the
major histocompatibility region (Interna-
tional Schizophrenia Consortium et al.,
2009; Shi et al., 2009; Stefansson et al.,
2009) raising the intriguing possibility of
an etiological role for an immune, autoim-
mune, or infectious process. In addition,182 Neuron 68, October 21, 2010 ª2010 Elsesome studies have highlighted the role
of alternative ways in which genetic varia-
tion might be etiological, including the
importance of copy number variation
(Sebat et al., 2009) and even compelling
empirical data that schizophrenia results
from the cumulative effects of thousands
of different genetic variants in an as yet
unknown biological pathway (International
Schizophrenia Consortium et al., 2009).
Even the most cursory review of the
GWAS literature reveals that the critical
ingredient to success is large samples
for initial discovery and replication. Sam-
ple size requirements can easily exceed
10,000 cases and 10,000 controls. Ob-
taining such historically massive sample
sizes is beyond the reach of any sin-
gle group. Therefore, close cooperation
among groups has become essential to
progress in human genetics.
The purpose of this Neuron NeuroView
is to describe the Psychiatric Genome-
Wide Association Consortium (PGC)
which was created in an attempt to
conduct large-scale mega-analyses of
GWAS data for psychiatric disorders.
Psychiatric diseases are compelling tar-
gets for genetics research—they are
mostly idiopathic, first-rank public health
problems, and cause enormous mor-
bidity, mortality, and personal/societal
cost. Moreover, despite considerable re-
search, little is known for certain about
disease etiology. The fact that disease
definition in psychiatry is descriptive
poses particular problems. The diag-
nostic process relies heavily on signs
and symptoms without recourse tovier Inc.biological means of distinguishing af-
fected from unaffected individuals. This
poses unique challenges for genetic
studies. Although the PGC’s focus has
been in the area of psychiatric genetics,
the organization and consortia approach
which the PGC exemplifies could be
a model for other disorders and more
broadly, even outside of genetics, for
other research communities applying
high-throughput analytic approaches to
biological problems.
GWAS Background
As the GWAS method has been re-
viewed extensively, only a brief descrip-
tion is given here and Table 1 provides
ample opportunities for further reading.
A GWAS for a human disease is usually
a variant of a cross-sectional case-control
study, the familiar workhorse in biomedi-
cine. Cases meet lifetime criteria for a
disease (e.g., schizophrenia) and controls
should havenevermet criteria and, ideally,
be through the period of risk. Each indi-
vidual in the sample is genotyped for a
predefined set of a million or more genetic
markers spaced across the genome. The
genetic markers are single nucleotide
polymorphisms (SNPs, ‘‘snips’’) which
are relatively straightforward to assay in
a highly multiplexed fashion. After careful
quality control, each SNP is tested for
association with disease. In effect, these
tests compare the allele frequencies in
cases versus controls, and a large case-
control difference suggests an etiological
role for a particular SNP or its genomic
region. Because of the large numbers of
Table 1. Published Descriptions of the GWAS Method
Citation Comment
Corvin et al., 2009 A ‘‘primer’’ on GWAS, covers
the major topics with annotations
suggesting additional readings
Attia et al., 2009a, 2009b
Pearson and Manolio, 2008
JAMA series for users of the GWAS literature
Altshuler and Daly, 2007
Hardy and Singleton, 2009
McCarthy and Hirschhorn, 2008
Notable reviews of the GWAS method
Chanock et al., 2007 Replication in human genetics
Manolio et al., 2007 Establishing consortia in human genetics
Neale and Purcell, 2008 Quality control of GWAS data
de Bakker et al., 2008 Meta-analysis of GWAS data
Psychiatric GWAS Consortium
Coordinating Committee et al., 2009
Psychiatric GWAS Consortium
Steering Committee, 2009
Cross-Disorder Phenotype
Group of the Psychiatric
GWAS Consortium, 2009
Series of papers describing the PGC
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ability mandate correction for multiple
comparisons.A typical type1error thresh-
old for genome-wide significance is often
taken to be 53 108 (akin to a Bonferroni
correction of 0.05 divided by 1 million
tests) (Pe’er et al., 2008).Psychiatric GWAS Consortium
(PGC): Background and Science
As increasing numbers of GWAS were
published in 2005–2006, it became
apparent that typical sample sizes (e.g.,
1000 cases and 1000 controls) did not
usually lead to associations that ex-
ceeded chance levels of significance.
Such findings provided, for the first time,
evidence that the genetic effect sizes for
common variation were considerably
smaller than had been appreciated. For
example, in the pre-GWAS era, many
investigators powered their studies to
detect genotypic relative risks of 1.54
(1000 cases/1000 controls, a = 5 3
108, and 90% power). Using the NHGRI
GWAS catalog (Hindorff et al., 2009;
Figure 1), the typical genotypic relative in
a GWAS is far smaller than appreciated
previously (median of 1.28) which neces-
sitates a sample size of over 3000 cases
and 3000 controls. To identify the 25th
percentile genotypic relative risk of 1.18
requires nearly 7000 cases and 7000
controls.Thus, assumptions about power and
sample size required revision; studies
which seemed well-powered when they
began were too small. It became obvious
that larger sample sizes were needed and
groups working together were the only
practical way to achieve this end. Consor-
tia were thus an immediate solution. The
concept of working together was influ-
encedby theexperiencesofotherbiomed-
ical disorders. For example, the initial three
GWAS for type 2 diabetes mellitus were
onlymodestly successful but joint analysis
revealed many more strongly significant
associations.
The PGC began on a teleconference in
March 2007 between principal investiga-
tors who had GWAS funded for attention
deficit hyperactivity disorder (ADHD),
bipolar disorder, major depressive dis-
order, and schizophrenia as part of a
Foundation for the NIH initiative (Manolio
et al., 2007). Even though, at the time,
this project was at early stages and as
no psychiatric GWAS had yet been pub-
lished, we were already concerned about
power and hence initiated plans for joint
analysis of our results. This effort rapidly
expanded to include autism, the other
majorpsychiatric disorderwithaconsider-
able body of GWAS data. Subsequently,
all investigators in the field with data for
these five disorders were invited to join
the PGC. All but one group invited has
joined.Neuron 68The overarching purpose of the PGC is
to conduct high-quality GWAS mega-
analyses in order to foster rapid progress
in what has been a complex and uncertain
scientific area. These results are meant to
inform research into ADHD, autism,
bipolar disorder, major depressive dis-
order, and schizophrenia along with
searches for genetic loci that predispose
to more than one disorder. The initial
iteration of the PGC had four scientific
aims, which were designed to facilitate
the overarching scientific goal of attempt-
ing to identify secure associations of
comprehensive assessment of common
genetic variation with five critically impor-
tant psychiatric diseases.
The first aim involved dataset harmoni-
zation. Experience has taught us that
unless this is conducted with expertise
and great care, inference is not secure.
Harmonization and quality control apply
to each step of the GWAS process—
ascertainment of subjects, diagnostic
procedures, genotyping, removal of sub-
jects, and SNPs with unconfident data
and with extensive searches for bias. For
the PGC, raw individual-level and deiden-
tified phenotype and genotype data from
each study were uploaded to a high-
performance computing cluster and
processed through a robust and compre-
hensive quality control pipeline conform-
ing to best-practice protocols in order to
minimize chances of false positive results
(e.g., due to population stratification).
As the individual studies used different
genotyping platforms, the cleaned data
were imputed against a widely used
panel of data from European subjects
(HapMap3) so that all studies had a
common set of genotypes. In addition,
considerable efforts weremade to harmo-
nize phenotype data by ensuring that
all studies used comparable diagnostic
constructs and to database item-level
data.
The second aim entailed within-
disorder meta-analyses—five different
mega-analyses of all available GWAS
data for ADHD, autism, bipolar disorder,
major depressive disorder, and schizo-
phrenia, to attempt to identify convincing
genotype-phenotype associations.
The point of the third aim is specific
to psychiatry. Throughout the history of
psychiatry, diagnoses have been made
based on signs and symptoms accrued, October 21, 2010 ª2010 Elsevier Inc. 183
Figure 1.
Depicted are 587 associations for 76 human diseases. Each association is plotted as its genotypic relative
risk by the risk allele frequency in controls (both on log10 scale). The insert shows the 10 diseases with the
greatest numbers of associations. Red crosses show findings for neurological disorders (Alzheimer
disease, amyotrophic lateral sclerosis, essential tremor, multiple sclerosis, narcolepsy, and Parkinson
disease). Psychiatric disorders are indicated with plus marks including autism (blue), mood disorders
(green), and schizophrenia (fuchsia). All other biomedical disorders are shown by gray dots.
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patient. Although test-retest reliability is
generally acceptable, these are funda-
mentally descriptive syndromes and their
validity is unknown. Moreover, there is
considerable overlap between disorders.
For example, people with autism often
have ADHD. Cases with schizophrenia
frequently have symptoms highly similar
to those with BIP and major depressive
disorder. Indeed, major depressive dis-
order and BIP are alike in that both in-
cludemajor depressive episodes whereas
BIP additionally has manic episodes.
Given that clinically derived definitions of
illness may not have ‘‘carved nature at
the joint’’ with respect to the fundamental
genetic architecture (Kendell and Brock-
ington, 1980; Kendell, 1989), This aim
attempts to identify convincing genetic
associations that are common to two or
more of ADHD, autism, bipolar disorder,
major depressive disorder, and schizo-
phrenia. This work could provide critical
insight into how these disorders are similar
and different.184 Neuron 68, October 21, 2010 ª2010 ElseThe fourth aim is related to data
sharing. Consistent with the goal of rapid
progress, we have been communicating
prepublication results widely. Where
informed consent and Ethical Committee
rulings allow, deidentified phenotype,
genotype, and mega-analysis results will
be deposited into controlled-access
repositories (e.g., dbGaP, NCBI Database
of Genotypes and Phenotypes) (Mailman
et al., 2007) in order to make these data
available for future use by the international
scientific community.
Since the formation of the PGC, as we
move forward, we plan for a new set of
aims to continue the work of the PGC.
The new aims include a comprehensive
assessment of copy number variation
and extension of the analytic pipeline to
encompass next-generation sequencing
data.
The Practical Side of the PGC
By virtue of the numbers of investigators,
subjects, and data points, the PGC is
the largest consortium and biologicalvier Inc.experiment in the history of psychiatry.
The PGC currently has over 160 investi-
gators from 65 institutions in 19 countries.
Membership has been extended to
groups with high-quality GWAS data
and usually includes the study principal
investigator and key collaborators. Join-
ing the PGC entails reading and agreeing
to the rules of behavior detailed in
a memorandum of understanding. Assent
is indicated by email and effectively
constitutes a pledge to behave with
integrity. The PGC sponsored a series of
papers outlining the history of genetic
inquiries in psychiatry, a framework for
interpretation of GWAS, and issues per-
taining to comorbidity between disorders
(Table 1).
Participation in the PGC is driven by
varying combinations of altruism and
enlightened self-interest. Some investiga-
tors are inherently collegial and enjoy
consortia whereas others would prefer to
work independently but have come to
believe cooperation is essential for prog-
ress. Others are motivated by different
imperatives and we are aware that some
in the field have chosen not to join given
difficulties in functioning comfortably
and effectively in a group context.
The PGC consists of a coordinating
committee, five disease working groups
(ADHD, autism, bipolar, major depressive
disorder, and schizophrenia), the cross-
disorder working group, and a statistical
analysis group that has a CNV subgroup.
Working group chairs are as follows:
ADHD, Dr. Stephen Faraone; autism,
Drs. Bernie Devlin and Mark Daly; bipolar
disorder, Drs. John Kelsoe and Pamela
Sklar; major depressive disorder, Dr. Pat-
rick Sullivan; schizophrenia, Dr. Pablo
Gejman; statistical analysis, Dr. Mark
Daly; cross-disorder, Drs. Nick Craddock,
Jordan Smoller, and Ken Kendler; and
CNV, Drs. Mark Daly, Steven Scherer,
and Jonathan Sebat. Dr. Sullivan also
chairs the coordinating committee. Addi-
tional GWAS for anorexia nervosa and
obsessive-compulsive disorder are be-
coming available and will become part
of the PGC in the near future. There are
notable computational demands for a
project of this scale. We are deeply
indebted to Dr. Danielle Posthuma (Vrije
University Amsterdam) for facilitating the
use of a cluster farm in the Netherlands
for data warehousing and analysis.
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a neutral platform for analyses.
From the beginning, the overall philos-
ophy of the PGC has been to be as inclu-
sive, democratic, transparent, and rapid
as possible. No single individual or group
dominates. The role of the coordinating
committee is to adjudicate procedural
issues of relevance to the whole consor-
tium (e.g., to integrate efforts of the
working groups and to secure the needed
resources). A metaphor for the relation-
ship between the coordinating committee
and the working groups is the recurrent
theme of United States history, the
tension between federalism and ‘‘states’
rights.’’ The belief is that the best science
will emerge if the balance is decidedly
shifted toward ‘‘states’ rights.’’ The
‘‘federal’’ coordinating committee has a
non-intrusive and facilitating role and all
other decisions are delegated to the
scientists who understand the issues
best. There are often differences of
opinion. These are almost always
resolved by discussion. Rarely, discus-
sion did not lead to resolution and neces-
sitated a vote (simple majority, one vote
per group contributing data).
A key principle has been that groups
participate in the PGC at a time appro-
priate for their group. In practice, this
was usually after their GWAS primary
manuscript was accepted for publication.
Participation in the PGC does not
preclude any other academic effort (for
courtesy, however, investigators inform
their colleagues about any competing
activities). An early decision adopted by
all working groups was to publish under
a consortium byline with all members of
that working group listed as ‘‘collabora-
tors’’ in PubMed (see http://www.ncbi.
nlm.nih.gov/pubmed/17554300 for an
example). This practical decision allowed
the focus to remain on collaborative
science and negated the otherwise inevi-
table jockeying for priority authorship
positions. As a result of the clear and
consistent application of these basic
principles, the PGC has been running
smoothly for several years despite its
large membership. We note that no one
who joined the PGC has quit.
The goal of the PGC is rapid and unfet-
tered progress. As part of the Memo-
randum of Understanding, PGCmembers
agreed that all genotype and phenotypedata should be kept strictly confidential
within that working group. Moreover,
when the analyses for a specific aim
were completed, the results could be
freely discussed and participants were
free to initiate follow-up experiments.
In the interests of maximal progress,
we encouraged prepublication sharing
of follow-up experiments. However, the
results could not be used in presentations
or publications without prior approval.
The PGC encourages a responsible
approach to management of intellectual
property derived from downstream dis-
coveries that is consistent with the re-
commendations of the NIH’s Best Prac-
tices for the Licensing of Genomic
Inventions and Research Tools Policy
(http://www.ott.nih.gov/policy/genomic_
invention.html and http://ott.od.nih.gov/
policy/research_tool.html). In particular,
management of patent applications in
a manner that restricts use of any find-
ings or that might diminish the value
and public benefit provided by these
resources is discouraged.
Finally, all PGSmembers were required
to share the commitment to protect the
confidentiality of data and to protect the
joint analysis activity by insuring that
no data were released or published in
advance of an agreed-upon group publi-
cation and/or data release.
How Can Genetics Inform
Neurobiology?
The fundamental goal of the PGC is to
derive ‘‘maps’’ of the genetic architecture
for the major psychiatric disorders,
ADHD, autism, bipolar disorder, major
depressive disorder, and schizophrenia.
What does this mean for neuroscientists
working on understanding the mecha-
nisms of these disorders? Or to clinicians
and patients looking for therapies or at
least a better understanding of these
disorders and their causes?
For scientists who study processes
fundamental to the development of the
central nervous system and its function
in health and disease, these results are
likely to be highly relevant. Genetic risk
factors will include a spectrum of varia-
tion, from rare variants of strong effect to
common variants of more subtle effect.
Moreover, these data are likely to uncover
novel similarities between currently dis-
tinctive disorders and new ways in whichNeuron 68genetic changes can lead to disease
(e.g., copy number variation and highly
polygenic models).
It has now been widely observed that
GWAS findings only infrequently implicate
the ‘‘usual suspects.’’ In other words,
when GWAS identifies a high-confidence
and replicated finding, the loci implicated
often point in a novel direction and these
new leads can then become targeted
priorities for more mechanistically ori-
ented experimental work. While the holy
grail of GWAS may be the identification
of a strongly associated risk allele, as
more associations emerge from GWAS
and other genomic approaches and these
findings are replicated, even apparently
modest risk alleles may point us
toward relevant biological pathways and
networks.
Historically, there has been a gap
between psychiatric genetics and neuro-
science. In an idealized universe, psychi-
atric genetics and neuroscience would
have rather symbiotic relations. In this
way, we may well find that a genetic,
molecular, or neuronal process being
studied in a lab for one set of reasons
ends up emerging as a potentially critical
factor for a psychiatric disorder, based
on genetic data. Ultimately, it’s this kind
of synergy, between genetics and bio-
logy, which will pave the path to true
understanding of how genotype confers
risk for phenotype and gives us the best
chance of really understanding these
disorders and paving the way for more
effective therapies.
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